A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 11 Oct 2018 Status changed from active, no longer recruiting to completed.
- 10 Nov 2017 Planned End Date changed from 1 Jun 2018 to 30 Jun 2018.
- 21 Dec 2015 Results published in the Celgene International SARL media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History